Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : UTRxM1-18
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UTR Submits IND for mRNA Drug Targeting c-MYC in First-in-Human Cancer Trial
Details : UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers, harnesses UTR’s proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with ultra-high precision.
Product Name : UTRxM1-18
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : UTRxM1-18
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable